

Abstract

Microwave-Assisted Synthesis and Butyrylcholinesterase Inhibitory Activity of New Azobenzene Derivatives †

Martina Donozo ¹, Valeria Cavallaro ¹, Ana Paula Murray ^{1,*}  and Carlos Javier Baier ² 

¹ Instituto de Química del Sur (INQUISUR-CONICET-UNS), Departamento de Química, Universidad Nacional del Sur, Bahía Blanca 8000, Argentina

² Laboratorio de Toxicología, Instituto de Ciencias Biológicas y Biomedicas del Sur (INBIOSUR), Universidad Nacional del Sur-CONICET, Bahía Blanca 8000, Argentina

* Correspondence: apmurray@uns.edu.ar

† Presented at the 8th International Electronic Conference on Medicinal Chemistry, 1–30 November 2022; Available online: <https://ecmc2022.sciforum.net/>.

Abstract: Cholinesterase inhibitors (ChEis) play an important role in enhancing cholinergic synaptic activity and, consequently, have therapeutic applications in the treatment of neurodegenerative diseases like Alzheimer’s disease (AD). The inhibition of the enzymes acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) avoids the degradation of the neurotransmitter acetylcholine and constitutes a pharmacotherapeutic strategy that has shown important efficacy reducing AD symptoms. Based on previous results obtained by our group and with the purpose of obtaining diverse and more effective compounds, a series of new azobenzene derivatives were designed and synthesized. Additionally, considering the powerful AChE inhibition displayed by this type of compounds it was decided in this work to expand the research by testing BChE inhibitory activity. Nine azobenzene derivatives, with different spacer lengths (4–8 carbons) and terminal tertiary amines, were synthesized by microwave-assisted synthesis and tested for biological activity in vitro. The synthesis was carried out using a microwave oven (in two steps) with a reaction time of around 20 min and moderate to good yields. In addition, cytotoxic properties of the compounds in SH-SY5Y human neuroblastoma cells will be tested. The inhibitory activity of BChE was determined using Ellman’s method. All the compounds synthesized were active against BChE, the one with a six carbon atom spacer and ethylbenzylamine moiety (IC_{50} : $6.621 \mu M \pm 0.001$) being the most effective. From these results we could establish that the optimum length for the spacer was six carbons and that diamines were less active than monoamines.

Keywords: azobenzene; Alzheimer’s disease; butyrylcholinesterase; microwave; cytotoxic



Citation: Donozo, M.; Cavallaro, V.; Murray, A.P.; Baier, C.J. Microwave-Assisted Synthesis and Butyrylcholinesterase Inhibitory Activity of New Azobenzene Derivatives. *Med. Sci. Forum* **2022**, *14*, 31. <https://doi.org/10.3390/ECMC2022-13464>

Academic Editor: Maria Emília Sousa

Published: 1 November 2022

Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Supplementary Materials: The following are available online at <https://www.mdpi.com/article/10.3390/ECMC2022-13464/s1>.

Author Contributions: A.P.M.: Conceptualization, Writing—review & editing, Project administration, Funding acquisition Supervision. C.J.B.: Conceptualization, Methodology, Writing—review & editing, Investigation, Supervision. V.C.: Investigation, Writing—original draft, Supervision. M.D.: Investigation, Writing—original draft. All authors have read and agreed to the published version of the manuscript.

Funding: This research was funded by Universidad Nacional del Sur (UNS), the National Council for Scientific and Technological Research (CONICET) and the National Agency of Scientific and Technological Promotion (ANPCYT) from Argentina.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.